Individual Lesion-Level Meta-Analysis Comparing Various Doses of Intracoronary Bolus Injection of Adenosine With Intravenous Administration of Adenosine for Fractional Flow Reserve Assessment.


Journal

Circulation. Cardiovascular interventions
ISSN: 1941-7632
Titre abrégé: Circ Cardiovasc Interv
Pays: United States
ID NLM: 101499602

Informations de publication

Date de publication:
01 2020
Historique:
entrez: 25 12 2019
pubmed: 25 12 2019
medline: 1 9 2020
Statut: ppublish

Résumé

Intravenous infusion of adenosine is considered standard practice for fractional flow reserve (FFR) assessment but is associated with adverse side-effects and is time-consuming. Intracoronary bolus injection of adenosine is better tolerated by patients, cheaper, and less time-consuming. However, current literature remains fragmented and modestly sized regarding the equivalence of intracoronary versus intravenous adenosine. We aim to investigate the relationship between intracoronary adenosine and intravenous adenosine to determine FFR. We performed a lesion-level meta-analysis to compare intracoronary adenosine with intravenous adenosine (140 µg/kg per minute) for FFR assessment. The search was conducted in accordance to the Preferred Reporting for Systematic Reviews and Meta-Analysis statement. Lesion-level data were obtained by contacting the respective authors or by digitization of scatterplots using custom-made software. Intracoronary adenosine dose was defined as; low: <40 µg, intermediate: 40 to 99 µg, and high: ≥100 µg. We collected 1972 FFR measurements (1413 lesions) comparing intracoronary with intravenous adenosine from 16 studies. There was a strong correlation (correlation coefficient =0.915; The present study documents clinically irrelevant differences in FFR values obtained with intracoronary versus intravenous adenosine. Intracoronary adenosine hence confers a practical and patient-friendly alternative for intravenous adenosine for FFR assessment.

Sections du résumé

BACKGROUND
Intravenous infusion of adenosine is considered standard practice for fractional flow reserve (FFR) assessment but is associated with adverse side-effects and is time-consuming. Intracoronary bolus injection of adenosine is better tolerated by patients, cheaper, and less time-consuming. However, current literature remains fragmented and modestly sized regarding the equivalence of intracoronary versus intravenous adenosine. We aim to investigate the relationship between intracoronary adenosine and intravenous adenosine to determine FFR.
METHODS
We performed a lesion-level meta-analysis to compare intracoronary adenosine with intravenous adenosine (140 µg/kg per minute) for FFR assessment. The search was conducted in accordance to the Preferred Reporting for Systematic Reviews and Meta-Analysis statement. Lesion-level data were obtained by contacting the respective authors or by digitization of scatterplots using custom-made software. Intracoronary adenosine dose was defined as; low: <40 µg, intermediate: 40 to 99 µg, and high: ≥100 µg.
RESULTS
We collected 1972 FFR measurements (1413 lesions) comparing intracoronary with intravenous adenosine from 16 studies. There was a strong correlation (correlation coefficient =0.915;
CONCLUSIONS
The present study documents clinically irrelevant differences in FFR values obtained with intracoronary versus intravenous adenosine. Intracoronary adenosine hence confers a practical and patient-friendly alternative for intravenous adenosine for FFR assessment.

Identifiants

pubmed: 31870178
doi: 10.1161/CIRCINTERVENTIONS.119.007893
doi:

Substances chimiques

Vasodilator Agents 0
Adenosine K72T3FS567

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e007893

Auteurs

Gilbert W M Wijntjens (GWM)

Heart Center (G.W.M.W., E.L.v.U., V.E.S., T.M., J.J.P., T.P.v.d.H.), locatie-AMC, the Netherlands.

Ellen L van Uffelen (EL)

Heart Center (G.W.M.W., E.L.v.U., V.E.S., T.M., J.J.P., T.P.v.d.H.), locatie-AMC, the Netherlands.

Mauro Echavarría-Pinto (M)

Hospital General ISSSTE - Facultad de Medicina, Universidad Autónoma de Querétaro, México (M.E.-P.).

Lorena Casadonte (L)

Department of Biomedical Engineering and Physics (L.C.), Amsterdam-Universitair Medische Centra, locatie-AMC, the Netherlands.

Valérie E Stegehuis (VE)

Heart Center (G.W.M.W., E.L.v.U., V.E.S., T.M., J.J.P., T.P.v.d.H.), locatie-AMC, the Netherlands.

Tadashi Murai (T)

Heart Center (G.W.M.W., E.L.v.U., V.E.S., T.M., J.J.P., T.P.v.d.H.), locatie-AMC, the Netherlands.

Koen M J Marques (KMJ)

Department of Cardiology, Amsterdam-Universitair Medische Centra, locatie VUmc, Amsterdam, the Netherlands (K.M.J.M.).

Myeong-Ho Yoon (MH)

Department of Cardiology, Ajou University, Suwon, Republic of Korea (M.-H.Y., S.-J.T.).

Seung-Jea Tahk (SJ)

Department of Cardiology, Ajou University, Suwon, Republic of Korea (M.-H.Y., S.-J.T.).

Gianni Casella (G)

Department of Cardiology, Ospedale Maggiore, Bologna, Italy (G.C.).

Antonio M Leone (AM)

Dipartimento di Scienze Cardiovascolari e Toraciche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy (A.M.L.).

Ramón López Palop (R)

Department of Cardiology, Hospital Universitario de San Juan de Alicante, San Juan de Alicante, Spain (R.L.-P.).

Christian Schlundt (C)

Department of Cardiology, University of Erlangen, Germany (C.S.).

Fernando Rivero (F)

Department of Cardiology, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Spain (F.R.).

Ricardo Petraco (R)

Imperial College London, United Kingdom (R.P.).

William F Fearon (WF)

Department of Cardiology, Stanford University School of Medicine, Stanford Cardiovascular Institute (W.F.F.).

Nils P Johnson (NP)

Weatherhead PET Center, Division of Cardiology, Department of Medicine, McGovern Medical School at UTHealth and Memorial Hermann Hospital, Houston (N.P.J.).

Allen Jeremias (A)

St Francis Hospital, Roslyn, Cardiovascular Research Foundation, New York, NY (A.J.).

Bon-Kwon Koo (BK)

Seoul National University College of Medicine, Republic of Korea (B.-K.K.).

Jan J Piek (JJ)

Heart Center (G.W.M.W., E.L.v.U., V.E.S., T.M., J.J.P., T.P.v.d.H.), locatie-AMC, the Netherlands.

Tim P van de Hoef (TP)

Heart Center (G.W.M.W., E.L.v.U., V.E.S., T.M., J.J.P., T.P.v.d.H.), locatie-AMC, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH